Viewpoint: CRISPR technology poses genuine risks, but that doesn’t justify crushing regulations – Genetic Literacy Project
Genetic Literacy Project |
Viewpoint: CRISPR technology poses genuine risks, but that doesn’t justify crushing regulations
Genetic Literacy Project The advances made possible by CRISPR could bring vast benefits to society, but the technology also poses risks. An out-of-control gene drive could drastically alter or even threaten a species. And editing the human genome raises risks both for … |
|
Your Daily Pharma Scoop: Abeona’s ABO-202, Revance Update, Ionis/Biogen’s New Collaboration
Seeking Alpha Analysis focus: Abeona Therapeutics. Today we will discuss Abeona Therapeutics (NASDAQ:ABEO), which is up more than 5% in early trading after announcing that the European Medicines Agency (NYSEMKT:EMA) has granted its gene therapy AB-202 an Orphan Drug … |
PMLiVE |
New centre aims to Catapult UK into cell and gene therapy lead
PMLiVE Thompson says the Catapult will help avoid the ‘invented here, exploited somewhere else’ syndrome. Being opened today by business secretary Greg Clark, the Cell and Gene Therapy Catapult is located in the biotech cluster in Stevenage, not far from … UK Boosts Cell and Gene Therapy with New Manufacturing CenterPharmaceutical Executive (press release) (blog) UK cuts ribbon on £60 million facility to boost cell and gene therapy industryThe Pharma Letter |